Tumor News and Research

RSS

Use of NMR in diagnostic research: an interview with Elaine Holmes, Imperial College

The Phenome Center developed out of the Olympic drug testing facility, and we've adapted it so that we use NMR spectrometry, which we have three spectrometers, and mass spectrometry, to take blood and urine from hundreds and thousands of people and profile them to get a biochemical fingerprint of every person.

From Bruker BioSpin - NMR, EPR and Imaging 1 Jul 2014

Ipsen submits Supplemental New Drug Application to FDA for Somatuline Depot 120mg injection

Ipsen today announced that it has submitted a Supplemental New Drug Application to the U.S. Food and Drug Administration for Somatuline Depot 120mg injection for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

1 Jul 2014

New approach may help develop more effective immunotherapy for metastatic melanoma

A new approach demonstrated that the recognition of unique cancer mutations appeared to be responsible for complete cancer regressions in two metastatic melanoma patients treated with a type of immunotherapy called adoptive T-cell therapy.

1 Jul 2014

Researchers develop new way to identify potential therapeutic targets for drug resistant melanoma

Moffitt Cancer Center researchers developed a new way to identify possible therapeutic targets for patients with drug resistant melanoma. It involves using liquid chromatography-multiple reaction monitoring mass spectrometry to measure biomarkers or molecules in blood and tissue that indicates cancer is present. These measurements can help researchers determine if a patient is responding to treatment.

1 Jul 2014

Affimed Therapeutics files Form F-1 registration statement for public offering of common stock

Affimed Therapeutics today announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission ("SEC") relating to a proposed initial public offering of its common shares.

30 Jun 2014

EMA accepts for review Merck’s pembrolizumab MAA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced the European Medicines Agency (EMA) has accepted for review a Marketing Authorization Application (MAA) for pembrolizumab (MK-3475), the company's investigational anti-PD-1 antibody, for the treatment of advanced melanoma.

30 Jun 2014

patients with KRAS wild-type MCRC can benefit from Cetuximab Or Bevacizumab With Combi Chemo Equivalent For patients with KRAS wild-type MCRC

For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona.

30 Jun 2014

Single gene defines difference between aggressive and non-aggressive forms of thymoma

For a rare form of cancer called thymoma, researchers have discovered a single gene defining the difference between a fast-growing tumor requiring aggressive treatment and a slow-growing tumor that doesn't require extensive therapy.

30 Jun 2014

BRI to present clinical-stage product data at International Symposium on Pediatric Neuro-Oncology

The Burzynski Research Institute, Inc. (BRI) announced today that it will present data on two of the Company's clinical-stage product candidates, Antineoplaston A10 injections (Atengenal®) and Antineoplaston AS2-1 injections (Astugenal®), at the 16th International Symposium on Pediatric Neuro-Oncology held in Singapore from June 28, 2014 to July 2, 2014.

28 Jun 2014

University of Louisville researchers take a step forward in battle against lung cancer

Researchers at the University of Louisville have uncovered a cadre of small molecules that tell certain proteins to kill lung cancer cells. The team, led by Chi Li, Ph.D., assistant professor of medicine, published its finding in the April 2014 issue of Molecular and Cellular Biology.

28 Jun 2014

Some cancer patients with aggressive tumors may benefit from anti-inflammatory drugs

New research raises the prospect that some cancer patients with aggressive tumors may benefit from a class of anti-inflammatory drugs used to treat rheumatoid arthritis.

28 Jun 2014

Researchers find way to diagnose aggressiveness of oral cancer

Studying mouth cancer in mice, researchers have found a way to predict the aggressiveness of similar tumors in people, an early step toward a diagnostic test that could guide treatment, according to researchers at Washington University School of Medicine in St. Louis.

28 Jun 2014

Non-Hodgkin lymphoma subgroups found to have different survival rates

A Mayo Clinic-led group of researchers has discovered three subgroups of a single type of non-Hodgkin lymphoma that have markedly different survival rates. These subgroups could not be differentiated by routine pathology but only with the aid of novel genetic tests, which the research team recommends giving to all patients with ALK-negative anaplastic large-cell lymphoma (ALCL). Findings are published in the journal Blood.

27 Jun 2014

UCSB researchers explore genetic underpinnings of nerve-cell spacing

The functional organization of the central nervous system depends upon a precise architecture and connectivity of distinct types of neurons.

27 Jun 2014

Interactions with other infections can trigger herpes virus to reactivate, shows research

The famous slogan is "A diamond is forever," but that phrase might be better suited to herpes: Unlike most viruses, which succumb to the immune system's attack, herpes remains in the body forever, lying in wait, sometimes reactivating years later.

27 Jun 2014

Surgical biopsies can be safely performed on selected patients with late-stage lung cancer

Researchers at UC Davis have determined that surgical biopsies can be safely performed on select patients with late-stage non-small cell lung cancer, which should enhance their access to drugs that target specific genetic mutations such as epidermal growth factor receptor (EGFR).

27 Jun 2014

Scientists report first successful step toward vaccine that targets mutation in brain cancer

Astrocytomas and oligodendrogliomas are subtypes of a brain cancer called 'glioma'. These incurable brain tumors arise from glial cells, a type of support cell found in the central nervous system.

26 Jun 2014

Foundation Medicine provides assistance to cancer patients, families seeking access to targeted therapies

Foundation Medicine, Inc. today announced that it has partnered with Patient Advocate Foundation (PAF) on a national program to provide assistance to patients with cancer and their families seeking access to targeted therapies.

26 Jun 2014

Applying math to study cell migration and dynamics of organisms

Cell migration, which is involved in wound healing, cancer and tumor growth, and embryonic growth and development, has been a topic of interest to mathematicians and biologists for decades.

26 Jun 2014

EnGeneIC plans for Phase 2a trial of EGFR-targeted doxorubicin-packaged EDV nanocells for GBM

EnGeneIC, Ltd., an emerging biopharmaceutical company focused on revolutionizing the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells, today announced plans to move forward with a Phase 2a clinical trial in the U.S. using its formulation of EGFR-targeted, EDV nanocells packaged with doxorubicin for the treatment of recurrent glioblastoma (GBM), a common and aggressive type of brain tumor.

26 Jun 2014

Tumor News and Research

Use of NMR in diagnostic research: an interview with Elaine Holmes, Imperial College

Ipsen submits Supplemental New Drug Application to FDA for Somatuline Depot 120mg injection

New approach may help develop more effective immunotherapy for metastatic melanoma

Researchers develop new way to identify potential therapeutic targets for drug resistant melanoma

Affimed Therapeutics files Form F-1 registration statement for public offering of common stock

EMA accepts for review Merck’s pembrolizumab MAA for treatment of advanced melanoma

patients with KRAS wild-type MCRC can benefit from Cetuximab Or Bevacizumab With Combi Chemo Equivalent For patients with KRAS wild-type MCRC

Single gene defines difference between aggressive and non-aggressive forms of thymoma

BRI to present clinical-stage product data at International Symposium on Pediatric Neuro-Oncology

University of Louisville researchers take a step forward in battle against lung cancer

Some cancer patients with aggressive tumors may benefit from anti-inflammatory drugs

Researchers find way to diagnose aggressiveness of oral cancer

Non-Hodgkin lymphoma subgroups found to have different survival rates

UCSB researchers explore genetic underpinnings of nerve-cell spacing

Interactions with other infections can trigger herpes virus to reactivate, shows research

Surgical biopsies can be safely performed on selected patients with late-stage lung cancer

Scientists report first successful step toward vaccine that targets mutation in brain cancer

Foundation Medicine provides assistance to cancer patients, families seeking access to targeted therapies

Applying math to study cell migration and dynamics of organisms

EnGeneIC plans for Phase 2a trial of EGFR-targeted doxorubicin-packaged EDV nanocells for GBM

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News